The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Examining mCRC Chemotherapy Costs, Patient Outcomes in Washington vs British Columbia

Todd Yezefski, MD
Published Online:2:51 PM, Tue June 12, 2018

Todd Yezefski, MD, a senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the results of a trial investigating cost and outcome differences in patients with metastatic colorectal cancer in the United States and Canada. Specifically, he looked at patients in Washington and British Columbia. This data was presented at the 2018 ASCO Annual Meeting.

He and his team found that the cost of chemotherapy treatments was almost double in Washington compared with British Columbia. While patients in Washington were paying almost $12,000 dollars per month per patient, those in British Columbia were only paying a little more than $6,000 dollars per month.

However, Yezefski noted that the outcomes did not differ between these 2 locations. The main reason behind this price gap comes down to the laws in Canadian government; prices are set around the median price, based on prices in multiple other countries. In the United States, the price is solely up to the pharmaceutical company while insurance companies are forced to pay that amount, he explains.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.